Sociedad Americana de Hirudoterapia

Hirudin ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation: roles of NLRP3-signaling pathway

Basic science / preclinical published in Mol Cell Biochem (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Farmacología salivalDesarrollo de fármacosBai Y et al. · Molecular and cellular biochemistry, 2023

Abstract

Severe hemorrhage shock and resuscitation (HSR) has been reported to induce myocardial ischemia-reperfusion injury (MIRI), resulting in a poor prognosis. Hirudin, an effective thrombin inhibitor, can offer protection against MIRI. This study aimed to determine if hirudin administration ameliorates HSR-induced MIRI and the underlying mechanism. A rat model of HSR was established by bleeding rats to a mean arterial blood pressure of 30-35 mmHg for 45 min and then resuscitating them with all the shed blood through the left femoral vein. After HSR, 1 mg/kg of hirudin was administrated immediately. At 24 h after HSR, the cardiac injury was assessed using serum CK-MB, cTnT, hematoxylin-eosin (HE) staining, echocardiography, M1-polarized macrophages, and pyroptosis-associated factors, including cleaved caspase-1, Gasdermin D (GSDMD) N-terminal, IL-1β, and IL-18 were measured by immunofluorescence and western blot assays. Nigericin, a unique agonist, was utilized to evaluate the responsibilities of NLRP3 signaling. Under the HSR condition, rats exhibited a significant increase in myocardial injury score, an elevation of serum cTnT, CK-MB levels, an aggrandization of M1-polarized macrophages, an upregulation of pyroptosis-associated factors, including cleaved caspase-1, GSDMD N-terminal, IL-1β, and IL-18, but a significant decrease in left ventricular ejection fraction (EF%) and a reduction of left ventricular fractional shortening (FS%), while hirudin administration partially restored the changes. However, the NLRP3 agonist nigericin reversed the cardioprotective effects of hirudin. We determined the cardioprotective effects of hirudin against HSR-induced MIRI. The mechanism may involve the inhibition of NLRP3-induced pyroptosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsRatsAnimalsMyocardial Reperfusion InjuryNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-18HirudinsShock, HemorrhagicStroke VolumeNigericinVentricular Function, LeftCaspase 1Signal Transduction

Resumen

Rat model of hemorrhagic shock + resuscitation shows hirudin (1 mg/kg) ameliorates myocardial ischemia-reperfusion injury via inhibition of NLRP3-induced pyroptosis. Restores left ventricular function and reduces M1-macrophage polarization.

Por qué esto importa para la hirudoterapia

This study investigated whether hirudin (1 mg/kg), described as an effective thrombin inhibitor, ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation (HSR). Hirudin partially restored left ventricular function, reduced serum CK-MB and cTnT, decreased M1-polarized macrophages and pyroptosis-associated factors (cleaved caspase-1, GSDMD N-terminal, IL-1β, IL-18), and the NLRP3 agonist nigericin reversed these cardioprotective effects, suggesting the mechanism involves inhibition of NLRP3-induced pyroptosis. The abstract does not describe hirudin as leech-derived, nor does it specify the route of administration. This is a single-dose animal study with no human data, and no leech application is involved; the leech connection rests solely on hirudin being a well-known thrombin inhibitor.

Citación

Hirudin ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation: roles of NLRP3-signaling pathway.

Bai Y et al. · Molecular and cellular biochemistry, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.